To the best of our knowledge, this is the first multicenter, real-world study analyzing the differences between PD-1 inhibitor plus EP chemotherapy and PD-L1 inhibitor plus EP chemotherapy on survival, efficacy, and safety in ES-SCLC patients from China. Here, CD274 is linked to small cell lung carcinoma.